OTCMKTS:IDXG Interpace Biosciences (IDXG) Stock Price, News & Analysis $1.70 -0.10 (-5.56%) As of 01:16 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Interpace Biosciences Stock (OTCMKTS:IDXG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Interpace Biosciences alerts:Sign Up Key Stats Today's Range$1.70▼$1.7750-Day Range$1.65▼$2.3052-Week Range$0.70▼$2.40Volume502 shsAverage Volume8,294 shsMarket Capitalization$7.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Read More Interpace Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreIDXG MarketRank™: Interpace Biosciences scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Interpace Biosciences. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Interpace Biosciences is -34.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Interpace Biosciences is -34.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInterpace Biosciences has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of Interpace Biosciences has been sold short.Short Interest Ratio / Days to CoverInterpace Biosciences has a short interest ratio ("days to cover") of 0.05, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Interpace Biosciences has recently increased by 30.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInterpace Biosciences does not currently pay a dividend.Dividend GrowthInterpace Biosciences does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.01 News SentimentInterpace Biosciences has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Interpace Biosciences this week, compared to 1 article on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Interpace Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders5.50% of the stock of Interpace Biosciences is held by insiders.Percentage Held by Institutions5.73% of the stock of Interpace Biosciences is held by institutions.Read more about Interpace Biosciences' insider trading history. Receive IDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDXG Stock News HeadlinesHead-To-Head Survey: Interpace Biosciences (OTCMKTS:IDXG) & Biotricity (NASDAQ:BTCY)May 29 at 5:03 AM | americanbankingnews.comReviewing Interpace Biosciences (OTCMKTS:IDXG) & Titan Medical (NASDAQ:TMDIF)May 26 at 4:07 AM | americanbankingnews.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 29 at 1:00 AM | Brownstone Research (Ad)PDI Is Yielding 15.93% After The Drop, And I Believe It's An Opportunity For Income InvestorsMay 24, 2026 | seekingalpha.comComparing Interpace Biosciences (OTCMKTS:IDXG) and Biotricity (NASDAQ:BTCY)May 19, 2026 | americanbankingnews.comInterpace Biosciences Announces First Quarter 2026 Financial and Business ResultsMay 12, 2026 | globenewswire.comPDI: Change Your ThinkingMay 9, 2026 | seekingalpha.comWestport Unveils High-Pressure CNG–HPDI System for North American Heavy-Duty Fleets at ACT Expo 2026April 30, 2026 | tipranks.comSee More Headlines IDXG Stock Analysis - Frequently Asked Questions How have IDXG shares performed this year? Interpace Biosciences' stock was trading at $1.2302 at the beginning of the year. Since then, IDXG shares have increased by 38.2% and is now trading at $1.70. How were Interpace Biosciences' earnings last quarter? Interpace Biosciences, Inc. (OTCMKTS:IDXG) announced its quarterly earnings data on Tuesday, May, 12th. The business services provider reported $0.03 EPS for the quarter. The business services provider earned $9.03 million during the quarter. Interpace Biosciences had a net margin of 65.25% and a trailing twelve-month return on equity of 219.07%. How do I buy shares of Interpace Biosciences? Shares of IDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Interpace Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Bristol Myers Squibb (BMY), Novavax (NVAX) and Histogenics (HSGX). Company Calendar Last Earnings5/12/2026Today5/29/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Services Current SymbolOTCMKTS:IDXG CIK1054102 Webwww.interpace.com Phone855-776-6419Fax862-207-7820Employees152Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$24.58 million Net Margins65.25% Pretax Margin8.65% Return on Equity219.07% Return on Assets105.05% Debt Debt-to-Equity RatioN/A Current Ratio2.51 Quick Ratio2.51 Sales & Book Value Annual Sales$38.73 million Price / Sales0.19 Cash Flow$5.48 per share Price / Cash Flow0.31 Book Value$5.21 per share Price / Book0.33Miscellaneous Outstanding Shares4,430,000Free Float4,185,000Market Cap$7.53 million OptionableNot Optionable Beta0.65 Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:IDXG) was last updated on 5/29/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
